Prenatal to Postnatal Renal and Genitourinary Anomalies - Genetics, Management and Outcomes - A Joint Course with ISPD - Short Course

Date of Release: May 1, 2020

CME, General CEU's, P.A.C.E.® Expiration Date: May 1, 2023

NSGC Credits Expiration Date: May 01, 2022

www.acmgeducation.net

Overview of renal and genitourinary anomalies from prenatal presentation to pediatric outcomes.

Target Audience

All healthcare professionals interested in the diagnosis, management, treatment and prevention of genetic conditions and increasing their understanding of the genetic basis of common, chronic health problems affecting both children and adults will find the programming applicable to their practice

Agenda

Louise E. Wilkins-Haug, MD, PhD, FACMG     Introductions and Overview

Anthony R. Gregg, MD, MBA, FACMG            Prenatal Screening for Sex Chromosome Aneuploidy - Ambiguity, Discordance and First Steps in Management

Louanne Hudgins, MD, FACMG                       Fetal Cystic Kidneys: Prenatal and Postnatal Considerations

Louise E. Wilkins-Haug, MD, PhD, FACMG     Sorting Out Posterior Urethral Valve Imposters

Ali G. Gharavi, MD                                           Genome-wide Approaches for Diagnosis of Kidney and Urogenital Disorders

Learning Objectives

At the conclusion of this session, participants should be able to:

1. Outline the pediatric expectations following a prenatal ultrasound with cystic kidneys
2. Review the variability of renal disease in the fetus
3. Demonstrate appropriate prenatal and postnatal diagnostic, management and counseling skills for cystic renal anomalies
4. Define the utility of noninvasive prenatal diagnosis (NIPT) for sex determination
5. Interpret discordancy between ultrasound determination of sex and genetic sex
6. Demonstrate the approach to a newborn with ambiguous genital
7. Illustrate the prenatal and postnatal variability in sex chromosome aneuploidies
8. Summarize the genetic conditions presenting with oligohydramnios
9. Examine the role of amniotic fluid on pulmonary development
10. Debate the efficacy of prenatal intervention for oligohydramnios
11. Formulate an approach to lower urinary outflow obstruction

Presenters

Louise E. Wilkins-Haug, MD, PhD, FACMG

Division Director, Maternal Fetal Medicine and Reproductive Genetics

Brigham & Women's Hospital

Anthony R. Gregg, MD, MBA, FACMG

ACMG and ACMG Foundation Board of Directors 

Chair of the Department of Obstetrics and Gynecology and Chief of Maternal Fetal Medicine at Baylor University Medical Center

Louanne Hudgins, MD, FACMG

Professor of Pediatrics, Division of Medical Genetics, Stanford University School of Medicine

Ali G. Gharavi, MD

Jay Meltzer Professor of Nephrology and Hypertension and serves as Chief of the Division of Nephrology at Columbia University Irving Medical Center

Financial Disclosures

Disclosure Statement

It is the policy of the American College of Medical Genetics and Genomics to plan and implement all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, committee members and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any commercial interests (see definition below) within the past 12 months that creates a real or apparent conflict of interest. Disclosure must include financial relationships of the individual and those of their spouse/partner. Individuals who do not disclose will be disqualified from participating in a CME activity.

This disclosure pertains to relationships with ACCME-defined commercial interests whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be managed prior to the educational activity. ACMG will identify, review and resolve all conflicts of interests prior to an educational activity being delivered to learners.

NOTE:

• ACMG will follow the ACCME’s expectation that no employees or owners of commercial interests will be involved as planners/faculty/presenters of a CME accredited activity.
• The ACCME definition of a commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
• The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
• Diagnostic laboratories are not considered commercial interests unless they are owned by or have a sister organization which is a commercial interest.

Louise E. Wilkins-Haug, MD, PhD, FACMG

Has no relevant financial relationships to disclose.

Anthony R. Gregg, MD, MBA, FACMG

Has no relevant financial relationships to disclose.

Louanne Hudgins, MD, FACMG

Has no relevant financial relationships to disclose.

Ali G. Gharavi, MD

Dr. Gharavi has disclosed that he is a consult for Astra Zeneca; has external grant/research support from

Renal Research Institute.

Educational Credit

Accreditation Statement

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE (Continuing Education for non-physicians): This activity has been approved for CE credits.
*The certificate is accepted by the ABMGG for certification.

Genetic Counselor Credit

The National Society of Genetic Counselors (NSGC) has authorized American College of Medical Genetics to offer up to 4.5 Category 1 contact hours for this activity. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

ACMG will report completed accredited sessions to NSGC for credit certificates on December 4, 2020, December 3, 2021 and July 8, 2022. Submissions outside of these parameters may incur a processing fee of $35.

P.A.C.E.® CEUs- Laboratory Directors and Laboratory Personnel

ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program. The American College of Medical Genetics and Genomics designates this OnDemand course for a maximum of 4.5 contact hours. ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider #50-11878. This course is registered # 20-775394 with CEBroker.  ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.®

Claiming your Educational Credits

Complete the activity, score 80% or better on the post-test, and carefully complete the evaluation form.

HIPAA Compliance

The ACMG supports medical information privacy.  While the ACMG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ACMG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ACMG-sponsored events has been properly authorized.  All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information.  If so, they were asked either to attest that a HIPAA-compliant consent form is on file at their institution, or to send ACMG a copy of the ACMG HIPAA compliance form. This information is on record at the ACMG Administrative Office and will be made available on request.

Content Validation

ACMG follows the ACCME policy on Content Validation for CME activities, which requires:

Content Validation and Fair Balance

1. ACMG follows the ACCME policy on Content Validation for CME activities, which requires:

1. All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
2. All scientific research referred to, reported or used in CME in support or justification of patient care recommendations must conform to the generally accepted standards of experimental design, data collection and analysis.

2. Activities that fall outside the definition of CME/CE; “Educational activities that serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession” (source: ACCME and AMA) will not be certified for credit. CME activities that promote recommendations, treatment, or manners of practicing medicine or pharmacy that are not within the definition of CME/CE or, are known to have risks or dangers that outweigh the benefits or, are known to be ineffective in the treatment of patients.
3. Presentations and CME/CE activity materials must give a balanced view of therapeutic options; use of generic names will contribute to this impartiality.  If the CME/CE educational materials or content includes trade names, where available, trade names from several companies must be used.

Off-label Uses of Products

When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.

Disclaimer

The ACMG does not endorse, or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or test, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.